Advances in the 5q- syndrome.

Advances in the 5q- syndrome.

The 5q- syndrome is the most distinct of all the myelodysplastic syndromes with a clear genotype/phenotype relationship. The significant progress made during recent years has been based on the determination of the commonly deleted region and the demonstration of haploinsufficiency for the ribosomal...

Bibliografski detalji
Glavni autori:	Boultwood, J, Pellagatti, A, McKenzie, A, Wainscoat, J
Format:	Journal article
Jezik:	English
Izdano:	2010

Slični predmeti

5q- syndrome.
od: Boultwood, J, i dr.
Izdano: (2012)

RECENT ADVANCES IN THE 5Q- SYNDROME
od: Andrea Pellagatti, i dr.
Izdano: (2015-05-01)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
od: Boultwood, J, i dr.
Izdano: (2012)

The 5q-syndrome.
od: Boultwood, J, i dr.
Izdano: (1994)

Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome.
od: Pellagatti, A, i dr.
Izdano: (2010)

Activation of the mTOR pathway by the amino acid (L)-leucine in the 5q- syndrome and other ribosomopathies.
od: Boultwood, J, i dr.
Izdano: (2013)

The 5q- syndrome.
od: Giagounidis, A, i dr.
Izdano: (2004)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
od: Pellagatti, A, i dr.
Izdano: (2011)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
od: Pellagatti, A, i dr.
Izdano: (2011)

Gene expression profiling in 5q-syndrome and myelodysplastic syndromes.
od: Pellagatti, A, i dr.
Izdano: (2003)

MOLECULAR DELINEATION OF THE CRITICAL REGION OF THE 5Q-CHROMOSOME IN THE 5Q-SYNDROME
od: Boultwood, J, i dr.
Izdano: (1993)

The human POP2 gene: identification, sequencing, and mapping to the critical region of the 5q- syndrome.
od: Fidler, C, i dr.
Izdano: (1999)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q)
od: Pellagatti, A, i dr.
Izdano: (2005)

Gene expression profiling in the myelodysplastic syndromes.
od: Pellagatti, A, i dr.
Izdano: (2005)

Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.
od: Jadersten, M, i dr.
Izdano: (2005)

Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q- syndrome: delineation of the critical region on 5q and identification of a 5q- breakpoint.
od: Boultwood, J, i dr.
Izdano: (1994)

MOLECULAR MAPPING OF UNCHARACTERISTICALLY SMALL 5Q DELETIONS IN 2 PATIENTS WITH THE 5Q- SYNDROME - DELINEATION OF THE CRITICAL REGION ON 5Q AND IDENTIFICATION OF A 5Q- BREAKPOINT
od: Boultwood, J, i dr.
Izdano: (1993)

Effects of L-leucine in 5q-syndrome and other RPS14-deficient erythroblasts
od: Yip, B, i dr.
Izdano: (2012)

Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts.
od: Yip, B, i dr.
Izdano: (2012)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q).
od: Pellagatti, A, i dr.
Izdano: (2004)

SF3B1 mutant myelodysplastic syndrome: Recent advances
od: Pellagatti, A, i dr.
Izdano: (2020)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
od: Jädersten, M, i dr.
Izdano: (2009)

ISOLATION OF NOVEL CDNA CLONES MAPPING TO THE CRITICAL REGION OF THE 5Q-CHROMOSOME IN THE 5Q-SYNDROME
od: Boultwood, J, i dr.
Izdano: (1994)

Homozygous deletion of FMS in a patient with the 5q- syndrome.
od: Boultwood, J, i dr.
Izdano: (1990)

Narrowing and genomic annotation of the critical region of the 5q-syndrome.
od: Boultwood, J, i dr.
Izdano: (2000)

Gene expression profiling of CD34+ cells in patients with the 5q- syndrome.
od: Boultwood, J, i dr.
Izdano: (2007)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.
od: Pellagatti, A, i dr.
Izdano: (2008)

Physical mapping of the human ATX1 homologue (HAH1) to the critical region of the 5q- syndrome within 5q32, and immediately adjacent to the SPARC gene.
od: Boultwood, J, i dr.
Izdano: (2000)

Molecular analysis of the 5q-syndrome
od: Boultwood, J
Izdano: (2007)

A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome.
od: Barlow, J, i dr.
Izdano: (2010)

Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes.
od: Fernandez-Mercado, M, i dr.
Izdano: (2013)

Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q- syndrome.
od: Jaju, R, i dr.
Izdano: (2000)

Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts.
od: Yip, B, i dr.
Izdano: (2013)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
od: Martin Jädersten, i dr.
Izdano: (2009-12-01)

NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
od: Fidler, C, i dr.
Izdano: (2004)

Activation of the mTOR signaling pathway by L-leucine in 5q-syndrome and other RPS14-deficient erythroblasts
od: Yip, B, i dr.
Izdano: (2013)

Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.
od: Pellagatti, A, i dr.
Izdano: (2006)

Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q- chromosome in some patients with the 5q- syndrome.
od: Boultwood, J, i dr.
Izdano: (1993)

Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome.
od: Boultwood, J, i dr.
Izdano: (2002)

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
od: Pellagatti, A, i dr.
Izdano: (2007)